PomdeSAR: Early Investigation of the Anti-CD38 Monoclonal Antibody Isatuximab in Combination With Pomalidomide/Dexamethasone in R/R MM

June 2-6, 2017; Chicago, Illinois

Phase I results suggest isatuximab-based combination safe, clinically active in highly treatment-experienced R/R MM.

Format: Microsoft PowerPoint (.ppt)

File Size: 857 KB

Released: June 8, 2017

Acknowledgements

Supported by educational grants by

AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

Cookie Settings